proxyvotesnow.com

Home › Companies › Akebia Therapeutics, Inc. › 2025-2026

Akebia Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Akebia Therapeutics, Inc.’s Form 8-K, filed 2026-06-22 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 9Reported items
  • 145Asset managers
  • 1,278Fund votes
  • 2026-06-17Meeting date

Proxy season: 2024-2025 2025-2026

Explore Akebia Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Akebia Therapeutics, Inc.

These tallies are Akebia Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-22 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Akebia Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-17
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Adrian Adams 102,040,314---- 41,312,58648,297,931 Majority: yes
Elect Director: Michael Rogers 102,377,117---- 40,975,78348,297,931 Majority: yes
Elect Director: LeAnne M. Zumwalt 97,926,409---- 45,426,49148,297,931 Majority: yes
Proposal 2: The Company's stockholders approved an amendment to the Company's Ninth Amended and Restated Certificate of Incorporation to (i) increase the number of authorized shares of capital stock from 375,000,000 to 525,000,000 and (ii) increase the number 102,504,10888,853,129293,594 ---- Majority: yes
Proposal 3: The Company's stockholders' approved, on a non-binding advisory basis, the compensation of the Company's named executive officers 89,838,83351,140,0102,374,057 --48,297,931 Majority: yes
Proposal 4: The Company's stockholders recommended, on a non-binding advisory basis, that future advisory votes on the compensation of the Company's named executive officers be held every year 112,927,161--7,080,470 ---- Outcome not stated
Proposal 5: The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 173,306,16515,754,2732,590,393 ---- Majority: yes

Source: Akebia Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-22 — read the filing on EDGAR.

How asset managers voted at the Akebia Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 145 asset managers that disclosed a Akebia Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Akebia Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DESCRIBED IN THE COMPANY'S PROXY STATEMENT.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

64% Majority: yes · of votes cast

FOR 64%AGAINST 36%
FOR: 89,838,833AGAINST: 51,140,010

Akebia Therapeutics, Inc.’s own tally for this item (“Proposal 3: The Company's stockholders' approved, on a non-binding advisory basis, the compensation of the Company's named executive officers”): 89,838,833 for, 51,140,010 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 268,258,243 outstanding shares: 33% for, 19% against (52.6% of the company cast a for/against vote).

The 141 asset managers below cast 98% of the shares they voted on this item FOR (65,840,601 for, 1,371,046 against).

FOR 98%
FOR: 65,840,601 (98.0%)AGAINST: 1,371,046 (2.0%)ABSTAIN: 11 (0.0%)
Largest asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DESCRIBED IN” at Akebia Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard15,157,584211 110For
BlackRock10,755,3823,825 00For
Fidelity8,261,4730 00For
State Street7,904,6574,289 00For
GEODE CAPITAL MANAGEMENT, LLC6,491,0660 00For
Charles Schwab4,036,9930 00For
Northern Trust1,269,1190 00For
Invesco01,232,214 00Against
MELLON INVESTMENTS Corp802,9490 00For
Voleon Capital Management LP758,9340 00For
AQR707,8250 00For
SEI677,0780 00For
Nuveen596,5990 00For
TIAA546,6650 00For
ACADIAN ASSET MANAGEMENT LLC531,3230 00For
Wellington493,9740 00For
T. Rowe Price465,6560 00For
Goldman Sachs425,4960 00For
Equitable403,1610 00For
Virtus308,0000 00For
CANADA PENSION PLAN INVESTMENT BOARD287,5000 00For
Victory Capital258,3400 00For
Two Sigma249,1390 00For
AllianceBernstein238,9300 00For
ALPS ETF Trust215,9120 00For

Showing the 25 largest of 141 asset managers. See all 141 in the interactive database.

2. APPROVAL, ON AN ADVISORY BASIS, OF THE FREQUENCY OF THE ADVISORY VOTE ON EXECUTIVE COMPENSATION.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

ONE YEAR 71%1 YEAR 28%

The 141 asset managers below cast 100% of the shares they voted on this item FOR (99,685 for, 0 against).

FOR: 99,685 (0.1%)ABSTAIN: 34 (0.0%)ONE YEAR: 47,860,024 (71.2%)1 YEAR: 18,970,040 (28.2%)THREE YEARS: 217,006 (0.3%)3 YEARS: 64,068 (0.1%)1.0: 488 (0.0%)1-YEAR: 187 (0.0%)3.0: 90 (0.0%)TWO YEARS: 25 (0.0%)2.0: 10 (0.0%)
Largest asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE FREQUENCY OF THE ADVISORY VOTE ON EXECUTIVE COMPENSATION.” at Akebia Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard00 340One Year
BlackRock00 001 Year
Fidelity00 00One Year
State Street00 00One Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
Charles Schwab00 001 Year
Northern Trust00 001 Year
Invesco00 00One Year
MELLON INVESTMENTS Corp00 00One Year
Voleon Capital Management LP00 00One Year
AQR00 00One Year
SEI00 001 Year
Nuveen00 00One Year
TIAA00 00One Year
ACADIAN ASSET MANAGEMENT LLC00 00One Year
Wellington00 001 Year
T. Rowe Price00 00One Year
Goldman Sachs00 00One Year
Equitable00 00One Year
Virtus00 00One Year
CANADA PENSION PLAN INVESTMENT BOARD00 00One Year
Victory Capital00 00One Year
Two Sigma00 00One Year
AllianceBernstein00 00One Year
ALPS ETF Trust00 00One Year

Showing the 25 largest of 141 asset managers. See all 141 in the interactive database.

3. APPROVAL OF AN AMENDMENT TO THE COMPANY'S NINTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF CAPITAL STOCK FROM 375,000,000 TO 525,000,000 AND TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 350,000,000 TO 500,000,000.

CAPITAL STRUCTUREMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

53.6% Majority: yes · of votes cast

FOR 53.6%AGAINST 46.4%
FOR: 102,504,108AGAINST: 88,853,129

Akebia Therapeutics, Inc.’s own tally for this item (“Proposal 2: The Company's stockholders approved an amendment to the Company's Ninth Amended and Restated Certificate of Incorporation to (i) increase the number of authorized shares of capital stock from 375,000,000 to 5”): 102,504,108 for, 88,853,129 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 268,258,243 outstanding shares: 38% for, 33% against (71% of the company cast a for/against vote).

The 49 asset managers below cast 99.9% of the shares they voted on this item FOR (34,766,003 for, 252 against).

FOR 99.9%
FOR: 34,766,003 (100.0%)AGAINST: 252 (0.0%)ABSTAIN: 1 (0.0%)
Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO THE COMPANY'S NINTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE ” at Akebia Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard13,275,517252 10For
Fidelity6,899,7970 00For
BlackRock4,256,3980 00For
State Street3,524,5730 00For
Charles Schwab2,018,4910 00For
TIAA546,6650 00For
Invesco541,0420 00For
Equitable403,1610 00For
Goldman Sachs343,5090 00For
SEI338,5390 00For
Virtus308,0000 00For
ALPS ETF Trust215,9120 00For
Lincoln Financial183,0000 00For
ProShares178,1880 00For
Direxion Shares ETF Trust152,6070 00For
AIG/SunAmerica137,4340 00For
AQR131,4030 00For
Victory Capital129,1700 00For
Global X110,6640 00For
Northern Trust108,9280 00For
Bridge Builder Trust107,3480 00For
Pacific Life99,3970 00For
CLEARWATER INVESTMENT TRUST94,6830 00For
Dimensional93,8910 00For
John Hancock65,9270 00For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

4. Election of three Class III Directors to serve until the Company's 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Adrian Adams

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%WITHHELD 29%
FOR: 102,040,314WITHHELD: 41,312,586

Akebia Therapeutics, Inc.’s own tally for this item (“Elect Director: Adrian Adams”): 102,040,314 for, 41,312,586 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 268,258,243 outstanding shares: 38% for, 15% withheld (53.4% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (34,567,571 for, 0 against).

FOR 99.4%
FOR: 34,567,571 (99.4%)ABSTAIN: 198,684 (0.6%)
Largest asset managers voting on “Election of three Class III Directors to serve until the Company's 2029 Annual Meeting of Stockholders and unt” at Akebia Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard13,238,5510 37,2180For
Fidelity6,899,7970 00For
BlackRock4,256,3980 00For
State Street3,520,0750 4,4980For
Charles Schwab2,018,4910 00For
TIAA546,6650 00For
Invesco541,0420 00For
Equitable403,1610 00For
Goldman Sachs343,5090 00For
SEI338,5390 00For
Virtus308,0000 00For
ALPS ETF Trust215,9120 00For
Lincoln Financial183,0000 00For
ProShares178,1880 00For
Direxion Shares ETF Trust152,6070 00For
AIG/SunAmerica137,4340 00For
AQR131,4030 00For
Victory Capital129,1700 00For
Global X110,6640 00For
Northern Trust108,9280 00For
Bridge Builder Trust107,3480 00For
Pacific Life99,3970 00For
CLEARWATER INVESTMENT TRUST94,6830 00For
Dimensional00 93,8910Abstain
John Hancock65,9270 00For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

5. Election of three Class III Directors to serve until the Company's 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: LeAnne M. Zumwalt

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

68% Majority: yes · of votes cast

FOR 68%WITHHELD 32%
FOR: 97,926,409WITHHELD: 45,426,491

Akebia Therapeutics, Inc.’s own tally for this item (“Elect Director: LeAnne M. Zumwalt”): 97,926,409 for, 45,426,491 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 268,258,243 outstanding shares: 37% for, 17% withheld (53.4% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (32,166,395 for, 0 against).

FOR 93%7%
FOR: 32,166,395 (92.5%)ABSTAIN: 2,599,860 (7.5%)
Largest asset managers voting on “Election of three Class III Directors to serve until the Company's 2029 Annual Meeting of Stockholders and unt” at Akebia Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard13,238,5330 37,2360For
Fidelity6,899,7970 00For
BlackRock4,256,3980 00For
State Street3,515,9990 8,5740For
Charles Schwab2,018,4910 00For
TIAA546,6650 00For
Invesco541,0420 00For
Equitable242,8910 160,2700For
Goldman Sachs343,5090 00For
SEI00 338,5390Abstain
Virtus00 308,0000Abstain
ALPS ETF Trust00 215,9120Abstain
Lincoln Financial183,0000 00For
ProShares00 178,1880Abstain
Direxion Shares ETF Trust00 152,6070Abstain
AIG/SunAmerica00 137,4340Abstain
AQR00 131,4030Abstain
Victory Capital00 129,1700Abstain
Global X00 110,6640Abstain
Northern Trust00 108,9280Abstain
Bridge Builder Trust107,3480 00For
Pacific Life99,3970 00For
CLEARWATER INVESTMENT TRUST00 94,6830Abstain
Dimensional00 93,8910Abstain
John Hancock00 65,9270Abstain

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

6. Election of three Class III Directors to serve until the Company's 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal: Michael Rogers

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%WITHHELD 29%
FOR: 102,377,117WITHHELD: 40,975,783

Akebia Therapeutics, Inc.’s own tally for this item (“Elect Director: Michael Rogers”): 102,377,117 for, 40,975,783 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 268,258,243 outstanding shares: 38% for, 15% withheld (53.4% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (34,600,700 for, 0 against).

FOR 99.5%
FOR: 34,600,700 (99.5%)ABSTAIN: 165,555 (0.5%)
Largest asset managers voting on “Election of three Class III Directors to serve until the Company's 2029 Annual Meeting of Stockholders and unt” at Akebia Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard13,250,7930 24,9760For
Fidelity6,899,7970 00For
BlackRock4,256,3980 00For
State Street3,520,0750 4,4980For
Charles Schwab2,018,4910 00For
TIAA546,6650 00For
Invesco541,0420 00For
Equitable403,1610 00For
Goldman Sachs343,5090 00For
SEI338,5390 00For
Virtus308,0000 00For
ALPS ETF Trust215,9120 00For
Lincoln Financial183,0000 00For
ProShares178,1880 00For
Direxion Shares ETF Trust152,6070 00For
AIG/SunAmerica137,4340 00For
AQR131,4030 00For
Victory Capital129,1700 00For
Global X110,6640 00For
Northern Trust108,9280 00For
Bridge Builder Trust107,3480 00For
Pacific Life99,3970 00For
CLEARWATER INVESTMENT TRUST94,6830 00For
Dimensional00 93,8910Abstain
John Hancock65,9270 00For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

7. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%
FOR: 173,306,165AGAINST: 15,754,273

Akebia Therapeutics, Inc.’s own tally for this item (“Proposal 5: The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 173,306,165 for, 15,754,273 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 268,258,243 outstanding shares: 65% for, 6% against (70% of the company cast a for/against vote).

The 49 asset managers below cast 99.9% of the shares they voted on this item FOR (34,766,064 for, 185 against).

FOR 99.9%
FOR: 34,766,064 (100.0%)AGAINST: 185 (0.0%)ABSTAIN: 7 (0.0%)
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING” at Akebia Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard13,275,71844 70For
Fidelity6,899,7970 00For
BlackRock4,256,3980 00For
State Street3,524,432141 00For
Charles Schwab2,018,4910 00For
TIAA546,6650 00For
Invesco541,0420 00For
Equitable403,1610 00For
Goldman Sachs343,5090 00For
SEI338,5390 00For
Virtus308,0000 00For
ALPS ETF Trust215,9120 00For
Lincoln Financial183,0000 00For
ProShares178,1880 00For
Direxion Shares ETF Trust152,6070 00For
AIG/SunAmerica137,4340 00For
AQR131,4030 00For
Victory Capital129,1700 00For
Global X110,6640 00For
Northern Trust108,9280 00For
Bridge Builder Trust107,3480 00For
Pacific Life99,3970 00For
CLEARWATER INVESTMENT TRUST94,6830 00For
Dimensional93,8910 00For
John Hancock65,9270 00For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

8. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 99.5%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (94,683 for, 0 against).

FOR: 94,683 (99.5%)ONE YEAR: 446 (0.5%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Akebia Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
CLEARWATER INVESTMENT TRUST94,6830 00For
TD Waterhouse Canada Inc.00 00One Year
Wilshire Advisors LLC00 00One Year

9. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (95,129 for, 0 against).

FOR: 95,129 (100.0%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Akebia Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
CLEARWATER INVESTMENT TRUST94,6830 00For
TD Waterhouse Canada Inc.3270 00For
Wilshire Advisors LLC1190 00For

Largest Akebia Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Akebia Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 268,258,243 shares outstanding at the time of that meeting.

Top Akebia Therapeutics, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 5.65%
2BlackRock 4.01%
3Fidelity 3.08%
4State Street 2.95%
5GEODE CAPITAL MANAGEMENT, LLC 2.42%
6Charles Schwab 1.50%
7Northern Trust 0.47%
8Invesco 0.46%
9MELLON INVESTMENTS Corp 0.30%
10Voleon Capital Management LP 0.28%

Reported Akebia Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Akebia Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
BlackRock 6.97% 13F
Vanguard Group 5.97% 13F
State Street 4.33% 13F
John P. Butler 2.42% DEF14A
Geode Capital 2.41% 13F
Goldman Sachs 1.34% 13F
Millennium Management 0.89% 13F
Charles Schwab 0.75% 13F
Steven K. Burke, M.D. 0.73% DEF14A
Northern Trust 0.73% 13F

Percentages above are of 268,258,243 shares outstanding, as reported by Akebia Therapeutics, Inc. on its Form 10-Q dated 2026-05-04 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Akebia Therapeutics, Inc.’s 10-Q dated 2026-05-04. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Akebia Therapeutics, Inc.'s shareholder meeting held 2026-06-17, in the 2025-2026 proxy season, 145 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,278 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS… — FOR was 64% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Akebia Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-22.

Akebia Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).